title: [The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people].
abstract: Atherosclerosis is a leading cause of obliterating diseases of the arteries in 80-90% of cases. The main pathogenetic mechanism is endothelial dysfunction, leading to hypertension, diabetes, congestive heart failure. The desire of modern society to improve the quality of life increases interest of human health in general and sexual health in particular, because the erectile function is an important factor in the quality of life, which makes us look for more effective methods of diagnosis, treatment and rehabilitation. The objective of the study was to assess the effectiveness of vasoactive tripeptide Vezugen in patients with vasculogenic erectile dysfunction as manifestation of atherosclerosis. Treatment results of erectile dysfunction in 41 patients were studied. A comparative analysis of clinical and instrumental parameters of blood flow in the main penile arteries before and after monotherapy was undertaken. The results show that the blood flow through the main artery of the penis after Vezugen treatment significantly improved both clinical and by objective indicators.
authors: K V
authors: KV
authors: Kitachev
authors: A B
authors: AB
authors: Sazonov
authors: K L
authors: KL
authors: Kozlov
authors: K Iu
authors: KIu
authors: Petrov
authors: A S
authors: AS
authors: Sliusarev
authors: V Kh
authors: VKh
authors: Khavinson
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001158:Arteries / Q000473:pathology; D050197:Atherosclerosis / Q000150:complications*; D016903:Drug Monitoring; D042783:Endothelial Cells / Q000187:drug effects; D007172:Erectile Dysfunction / Q000503:physiopathology / Q000523:psychology*; D006801:Humans; D018783:Impotence, Vasculogenic / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000008:administration & dosage / Q000009:adverse effects; D010413:Penis / Q000098:blood supply*; D020011:Protective Agents / Q000008:administration & dosage / Q000009:adverse effects; D011788:Quality of Life; D016896:Treatment Outcome; D018616:Ultrasonography, Doppler, Duplex / Q000379:methods
chemical_list: D009842:Oligopeptides; D020011:Protective Agents; C533570:lysyl-glutamyl-aspartic acid